Bacteroides thetaiotaomicron ameliorates mouse hepatic steatosis through regulating gut microbial composition, gut-liver folate and unsaturated fatty acids metabolism

References

• Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212–16. doi:10.1016/S0140-6736(20)32511-3.
   PubMed Web of Science ®Google Scholar
• Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, Kleiner DE, Brunt E, Bugianesi E, Yki-Järvinen H. International consensus panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.e1. doi:10.1053/j.gastro.2019.11.312.
   PubMed Web of Science ®Google Scholar
• Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism. 2022;126:154925. doi:10.1016/j.metabol.2021.154925.
   PubMed Web of Science ®Google Scholar
• Guo K, Xu S, Zeng Z. “Liver-gut” axis: a target of traditional Chinese medicine for the treatment of non-alcoholic fatty liver disease. Front Endocrinol (Lausanne). 2022;13:1050709. doi:10.3389/fendo.2022.1050709.
   PubMed Web of Science ®Google Scholar
• Gauffin Cano P, Santacruz A, Moya Á, Sanz Y. Bacteroides uniformis CECT 7771 ameliorates metabolic and immunological dysfunction in mice with high-fat-diet induced obesity. PloS ONE. 2012;7(7):e41079. doi:10.1371/journal.pone.0041079.
   PubMed Web of Science ®Google Scholar
• Kim S, Lee Y, Kim Y, Seo Y, Lee H, Ha J, Lee J, Choi Y, Oh H, Yoon Y. et al. Akkermansia muciniphila prevents fatty liver disease, decreases serum triglycerides, and maintains gut homeostasis. Appl Environ Microbiol. 2020;86(7):e03004–19. doi:10.1128/AEM.03004-19.
   PubMed Web of Science ®Google Scholar
• Lee HB, Do MH, Jhun H, Ha SK, Song HS, Roh SW, Chung WH, Nam YD, Park HY. Amelioration of hepatic steatosis in mice through bacteroides uniformis CBA7346-mediated regulation of high-fat diet-induced insulin resistance and Lipogenesis. Nutrients. 2021;13(9):2989. doi:10.3390/nu13092989.
   PubMed Web of Science ®Google Scholar
• Meroni M, Longo M, Dongiovanni P. The role of probiotics in nonalcoholic fatty liver disease: a new insight into therapeutic strategies. Nutrients. 2019;11(11):2642. doi:10.3390/nu11112642.
   PubMed Web of Science ®Google Scholar
• Tang Y, Huang J, Zhang WY, Qin S, Yang YX, Ren H, Yang QB, Hu H. Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2019;12:1756284819878046. doi:10.1177/1756284819878046.
   Web of Science ®Google Scholar
• Zhao Z, Chen L, Zhao Y, Wang C, Duan C, Yang G, Niu C, Li S. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation. Appl Microbiol Biotechnol. 2020;104(12):5273–5282. doi:10.1007/s00253-020-10633-9.
   PubMed Web of Science ®Google Scholar
• Li H, Liu NN, Li JR, Dong B, Wang MX, Tan JL, Wang XK, Jiang J, Lei L, Li HY. et al. Combined use of bicyclol and berberine alleviates mouse nonalcoholic fatty liver disease. Front Pharmacol. 2022;13:843872. doi:10.3389/fphar.2022.843872.
   PubMed Web of Science ®Google Scholar
• Zocco MA, Ainora ME, Gasbarrini G, Gasbarrini A. Bacteroides thetaiotaomicron in the gut: molecular aspects of their interaction. Dig Liver Dis. 2007;39(8):707–12. doi:10.1016/j.dld.2007.04.003.
   PubMedGoogle Scholar
• Sangineto M, Grander C, Grabherr F, Mayr L, Enrich B, Schwarzler J, Dallio M, Bukke VN, Moola A, Moschetta A. et al. Recovery of bacteroides thetaiotaomicron ameliorates hepatic steatosis in experimental alcohol-related liver disease. Gut Microbes. 2022;14(1):2089006. doi:10.1080/19490976.2022.2089006.
   PubMed Web of Science ®Google Scholar
• Liu R, Hong J, Xu X, Feng Q, Zhang D, Gu Y, Shi J, Zhao S, Liu W, Wang X. et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med. 2017;23(7):859–868. doi:10.1038/nm.4358.
   PubMed Web of Science ®Google Scholar
• Kasubuchi M, Hasegawa S, Hiramatsu T, Ichimura A, Kimura I. Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients. 2015;7(4):2839–49. doi:10.3390/nu7042839.
   PubMed Web of Science ®Google Scholar
• Cao Y, Pan Q, Cai W, Shen F, Chen GY, Xu LM, Fan JG. Modulation of gut microbiota by Berberine improves steatohepatitis in high-fat diet-fed BALB/C mice. Arch Iran Med. 2016;19:197–203.
   PubMed Web of Science ®Google Scholar
• Huang M, Kim HG, Zhong X, Dong C, Zhang B, Fang Z, Zhang Y, Lu X, Saxena R, Liu Y. et al. Sestrin 3 protects against diet-induced nonalcoholic steatohepatitis in mice through suppression of transforming growth factor β signal transduction. Hepatology. 2020;71(1):76–92. doi:10.1002/hep.30820.
   PubMed Web of Science ®Google Scholar
• Wang M, Li J, Li H, Dong B, Jiang J, Liu N, Tan J, Wang X, Lei L, Li H. et al. Down-regulating the high level of 17-beta-hydroxysteroid dehydrogenase 13 plays a therapeutic role for non-alcoholic fatty liver disease. Int J Mol Sci. 2022;23(10):5544. doi:10.3390/ijms23105544.
   PubMed Web of Science ®Google Scholar
• Stojanov S, Berlec A, Štrukelj B. The influence of probiotics on the firmicutes/bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease. Microorganisms. 2020;8(11):1715. doi:10.3390/microorganisms8111715.
   PubMed Web of Science ®Google Scholar
• Sid V, Siow YL, K O. Role of folate in nonalcoholic fatty liver disease. Can J Physiol Pharmacol. 2017;95(10):1141–1148. doi:10.1139/cjpp-2016-0681.
   PubMed Web of Science ®Google Scholar
• Qiao S, Bao L, Wang K, Sun S, Liao M, Liu C, Zhou N, Ma K, Zhang Y, Chen Y. et al. Activation of a specific gut bacteroides-folate-liver axis benefits for the alleviation of nonalcoholic hepatic steatosis. Cell Rep. 2020;32(6):108005. doi:10.1016/j.celrep.2020.108005.
   PubMed Web of Science ®Google Scholar
• de Castro GS, Calder PC, de Castro GS. Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. Clin Nutr. 2018;37(1):37–55. doi:10.1016/j.clnu.2017.01.006.
   PubMed Web of Science ®Google Scholar
• Zhou H, Urso CJ, Jadeja V. Saturated fatty acids in obesity-associated inflammation. J Inflamm Res. 2020;13:1–14. doi:10.2147/JIR.S229691.
   PubMed Web of Science ®Google Scholar
• Hliwa A, Ramos-Molina B, Laski D, Mika A, Sledzinski T. The role of fatty acids in non-alcoholic fatty liver disease progression: an update. Int J Mol Sci. 2021;22(13):22. doi:10.3390/ijms22136900.
   Web of Science ®Google Scholar
• Nagumalli SK, Willett RA, de Conti A, Tryndyak VP, Avigan MI, da Costa GG, Beland FA, Rusyn I, Pogribny IP, da Costa GG. Lipidomic profiling of the hepatic esterified fatty acid composition in diet-induced nonalcoholic fatty liver disease in genetically diverse Collaborative Cross mice. J Nutr Biochem. 2022;109:109108. doi:10.1016/j.jnutbio.2022.109108.
   PubMed Web of Science ®Google Scholar
• Spooner MH, Jump DB. Nonalcoholic fatty liver disease and omega-3 fatty acids: mechanisms and clinical use. Annu Rev Nutr. 2023;43(1):199–223. doi:10.1146/annurev-nutr-061021-030223.
   PubMedGoogle Scholar
• Cho SH, Cho YJ, Park JH. The human symbiont bacteroides thetaiotaomicron promotes diet-induced obesity by regulating host lipid metabolism. J Microbiol. 2022;60(1):118–127. doi:10.1007/s12275-022-1614-1.
   PubMed Web of Science ®Google Scholar
• Hu W, Gao W, Liu Z, Fang Z, Wang H, Zhao J, Zhang H, Lu W, Chen W. Specific strains of faecalibacterium prausnitzii ameliorate nonalcoholic fatty liver disease in mice in association with gut microbiota regulation. Nutrients. 2022;14(14):2945. doi:10.3390/nu14142945.
   PubMed Web of Science ®Google Scholar
• Zafar H, Saier MH. Gut bacteroides species in health and disease. Gut Microbes. 2021;13(1):1–20. doi:10.1080/19490976.2020.1848158.
   PubMed Web of Science ®Google Scholar
• Le HH, Lee MT, Besler KR, Johnson EL. Host hepatic metabolism is modulated by gut microbiota-derived sphingolipids. Cell Host & Microbe. 2022;30(6):798–808.e7. doi:10.1016/j.chom.2022.05.002.
   PubMed Web of Science ®Google Scholar
• Wang Y, Shou JW, Li XY, Zhao ZX, Fu J, He CY, Feng R, Ma C, Wen BY, Guo F. et al. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism. Metabolism. 2017;70:72–84. doi:10.1016/j.metabol.2017.02.003.
   PubMed Web of Science ®Google Scholar
• Li X, Su C, Jiang Z, Yang Y, Zhang Y, Yang M, Zhang X, Du Y, Zhang J, Wang L. et al. Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome. NPJ Biofilms Microbio. 2021;7(1):36. doi:10.1038/s41522-021-00205-8.
   PubMed Web of Science ®Google Scholar
• Thaiss CA, Itav S, Rothschild D, Meijer MT, Levy M, Moresi C, Dohnalová L, Braverman S, Rozin S, Malitsky S. et al. Persistent microbiome alterations modulate the rate of post-dieting weight regain. Nature. 2016;540(7634):544–551. doi:10.1038/nature20796.
   PubMed Web of Science ®Google Scholar
• Guirro M, Costa A, Gual-Grau A, Herrero P, Torrell H, Canela N, Arola L, Nerurkar PV. Effects from diet-induced gut microbiota dysbiosis and obesity can be ameliorated by fecal microbiota transplantation: a multiomics approach. PloS ONE. 2019;14(9):e0218143. doi:10.1371/journal.pone.0218143.
   PubMed Web of Science ®Google Scholar
• Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V, Henrissat B, Bain JR. et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Sci. 2013;341(6150):1241214. doi:10.1126/science.1241214.
   PubMed Web of Science ®Google Scholar
• Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM. et al. Cross-talk between akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013;110(22):9066–71. doi:10.1073/pnas.1219451110.
   PubMed Web of Science ®Google Scholar
• da Silva RP, Kelly KB, Al Rajabi A, Jacobs RL, da Silva RP. Novel insights on interactions between folate and lipid metabolism. Biofactors. 2014;40(3):277–283. doi:10.1002/biof.1154.
   PubMed Web of Science ®Google Scholar
• Li H, Liu NN, Li JR, Wang MX, Tan JL, Dong B, Lan P, Zhao LM, Peng ZG, Jiang JD. Bicyclol ameliorates advanced liver diseases in murine models via inhibiting the IL-6/STAT3 signaling pathway. Biomed Pharmacother. 2022;150:113083. doi:10.1016/j.biopha.2022.113083.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21. doi:10.1002/hep.20701.
   PubMed Web of Science ®Google Scholar
• Dos Anjos Cassado A. F4/80 as a major Macrophage Marker: the case of the peritoneum and spleen. Results Probl Cell Differ. 2017;62:161–179. doi:10.1007/978-3-319-54090-0_7.
   PubMedGoogle Scholar